The above findings imply that, when hyper-ERK activity in cancer is suppressed by ERK pathway-targeted therapeutics, PHLDA1/2 are downregulated and, therefore, AKT is activated by releasing from the PHLDA1/2-mediated inhibition. This evidence concerns the gene MAPK1 and cancer.